Teva makes $82 per share offer for Mylan

TEL AVIV/NEW YORK (Reuters) - Generic drugmaker Teva Pharmaceutical Industries Ltd. said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash. Teva said the offer was a 48-percent premium to the stock price of Mylan on March 10, 2015, which it said was "the last day of trading prior to widespread speculation of a transaction between Teva and Mylan." (Reporting by Caroline Humer; Editing by Alden Bentley)

via Health News Headlines - Yahoo News http://ift.tt/1Jq1RTt